Lincoln Pharmaceuticals reported a consolidated net profit of ₹87.89 crore for the financial year ended March 31, 2026, representing a 6.74% increase from ₹82.35 crore in the previous year. Revenue from operations for FY26 stood at ₹704.48 crore, a growth of 9.10% compared to ₹645.71 crore in FY25. The board has recommended a dividend of 18%, or ₹1.80 per share, on equity shares of face value ₹10 each for the year ended March 31, 2026, subject to shareholder approval at the upcoming annual general meeting. The statutory auditors, Samir M. Shah & Associates, issued an unmodified opinion on the audited standalone and consolidated financial results.

For the quarter ended March 31, 2026 (Q4FY26), the consolidated net profit stood at ₹11.63 crore, a marginal increase of 0.52% from ₹11.57 crore in the corresponding quarter of the previous year. Consolidated revenue from operations in Q4FY26 rose 13.50% year-on-year to ₹183.08 crore, while consolidated EBITDA for the quarter stood at ₹20.66 crore. The company noted that financial performance in Q4FY26 was impacted by the war and global scenario.

Consolidated Financial Performance

The table below presents the consolidated financial performance for Q4FY26 and the full year FY26 against the corresponding prior periods.

Standalone Q4 Performance

On a standalone basis, Lincoln Pharmaceuticals reported Q4 net profit of 116M Rupees, broadly flat compared to 116M Rupees in the same quarter of the previous year. Standalone revenue for Q4 came in at 1.9B Rupees, up from 1.68B Rupees year-on-year, reflecting continued topline momentum. However, standalone EBITDA declined to 248M Rupees from 267M Rupees in the year-ago period, with the standalone EBITDA margin contracting to 13.26% from 15.90% year-on-year.

Operational Highlights and Outlook

The company is targeting a revenue of ₹1,000 crore within the next three years, aiming for a 15-18% annual growth rate. This strategy is driven by strong performance in cardiac, diabetic, dermatology, and ENT segments. Lincoln Pharmaceuticals exports to over 60 countries and plans to expand its footprint to 90 countries over the next 2-3 years, leveraging recent entry into the Canadian market and approvals from TGA - Australia and EU GMP.

CRISIL Ratings reaffirmed its 'CRISIL A/Stable/CRISIL A1' ratings on the bank facilities of the company. Foreign Institutional Investors (FIIs) increased their stake to 5.20% as on March 31, 2026, compared to 5.00% in the previous year, while Domestic Institutional Investors (DIIs) held 1.08%. The company maintains a debt-free balance sheet and continues to invest in research and manufacturing capabilities.

Lincoln Pharmaceuticals Ltd has notified the stock exchanges of an upcoming Board of Directors meeting, scheduled pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation, dated May 18, 2026, was addressed to both the National Stock Exchange of India Limited and BSE Limited.

Board Meeting Details

The board meeting is set to be held on Thursday, May 28, 2026. The key agenda items to be considered at the meeting are outlined below:

Trading Window Closure

In continuation of the company's earlier disclosure on closure of the trading window dated March 31, 2026, Lincoln Pharmaceuticals has confirmed that the trading window has been closed for trading in the company's securities from April 01, 2026, pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will reopen after the expiry of 48 hours from the time the financial results become generally available to the public.

The intimation was signed by Trusha Shah, Company Secretary and Compliance Officer of Lincoln Pharmaceuticals Ltd, and digitally authenticated on May 18, 2026. The company is headquartered at "Lincoln House", Science City Road, Sola, Ahmedabad-380 060, Gujarat, India.